Is pharma's current penchant for M&A the right way to tackle patent-cliff setbacks?
The FT reports that the temperatures of AZ's investors are reaching feverish proportions as CEO David Brennan continues to reject calls for some sizable deals.
Watson Pharmaceuticals ($WPI) isn't just eyeing a deal for generics rival Actavis.
After resisting a bidfrom Valeant, ISTA went to Bausch & Lomb for 40% more.
The Canadian drugmaker has made yet another acquisition. This time, it's an OTC company in a deal potentially worth $180 million.
This week's M&A speculation continues with a blog post in The Guardian is saying Forest Laboratories ($FRX) is a prime target for pick up by AstraZeneca ($AZN).
The generic world was abuzz yesterday after rumors surfaced that Watson Pharmaceuticals could buy Actavis for about $7 billion.
Given the measly growth projections for U.S. and Europe, it's no surprise that expansion-minded drugmakers are looking eastward.
The Rovati family isn't making it easy for anyone interested in bidding on Rottapharm. According to a report in Reuters, Mylan ($MYL) has walked away from the bargaining table after negotiators failed to overcome the family's demand that it remain in control of the company, without showing any flexibility on the price. And something had to give.
Bayer CEO Marijn Dekkers thinks Pfizer ($PFE) is most likely to spin off its animal health unit. But the German company made a preliminary offer anyway, Dow Jones reports, citing the Financial Times Deutschland.